HRP20171848T1 - Upotreba malononitrilamida za neuropatsku bol - Google Patents
Upotreba malononitrilamida za neuropatsku bol Download PDFInfo
- Publication number
- HRP20171848T1 HRP20171848T1 HRP20171848TT HRP20171848T HRP20171848T1 HR P20171848 T1 HRP20171848 T1 HR P20171848T1 HR P20171848T T HRP20171848T T HR P20171848TT HR P20171848 T HRP20171848 T HR P20171848T HR P20171848 T1 HRP20171848 T1 HR P20171848T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- neuropathic pain
- syndrome
- pain
- use according
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title claims 19
- 208000021722 neuropathic pain Diseases 0.000 title claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 230000003902 lesion Effects 0.000 claims 7
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000001387 Causalgia Diseases 0.000 claims 2
- 206010064012 Central pain syndrome Diseases 0.000 claims 2
- 208000004983 Phantom Limb Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 206010002703 Anterior Spinal Artery Syndrome Diseases 0.000 claims 1
- 208000004020 Brain Abscess Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000019736 Cranial nerve disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019973 Herpes virus infection Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010042928 Syringomyelia Diseases 0.000 claims 1
- 206010064961 Thalamic infarction Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000035562 Wallenberg syndrome Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 208000012790 cranial neuralgia Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000002587 enol group Chemical group 0.000 claims 1
- 210000000609 ganglia Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000007654 ischemic lesion Effects 0.000 claims 1
- 208000004343 lateral medullary syndrome Diseases 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000005989 paraneoplastic polyneuropathy Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40819510P | 2010-10-29 | 2010-10-29 | |
| EP10014122 | 2010-10-29 | ||
| EP11784418.3A EP2632451B1 (en) | 2010-10-29 | 2011-10-28 | Use of malononitrilamides in neuropathic pain |
| PCT/EP2011/005452 WO2012055567A2 (en) | 2010-10-29 | 2011-10-28 | Use of malononitrilamides in neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171848T1 true HRP20171848T1 (hr) | 2018-02-09 |
Family
ID=44992853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171848TT HRP20171848T1 (hr) | 2010-10-29 | 2017-11-28 | Upotreba malononitrilamida za neuropatsku bol |
Country Status (16)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| EP2847158A4 (en) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| JP6202287B2 (ja) | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| JP2015518855A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 粘膜炎の治療のための組成物および方法 |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
| CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
| JP7090599B2 (ja) * | 2016-09-24 | 2022-06-24 | 山東亨利醫藥科技有限責任公司 | ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用 |
| DK3928772T3 (da) * | 2020-06-26 | 2024-08-19 | Algiax Pharmaceuticals Gmbh | Nanopartikulær sammensætning |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB9200275D0 (en) | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2727628B1 (fr) * | 1994-12-02 | 1997-01-10 | Roussel Uclaf | Application des derives de 3-cycloalkyl-propanamide a titre de medicaments analgesiques |
| US6566395B1 (en) * | 1999-05-25 | 2003-05-20 | Biomedicines, Inc. | Methods of treating proliferative disorders |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| DK2608782T3 (en) * | 2010-08-24 | 2016-09-05 | Algiax Pharmaceuticals Gmbh | New use of leflunomide malononitrilamider |
-
2011
- 2011-10-28 PL PL11784418T patent/PL2632451T3/pl unknown
- 2011-10-28 NO NO11784418A patent/NO2632451T3/no unknown
- 2011-10-28 PT PT117844183T patent/PT2632451T/pt unknown
- 2011-10-28 DK DK11784418.3T patent/DK2632451T3/en active
- 2011-10-28 SI SI201131372T patent/SI2632451T1/en unknown
- 2011-10-28 CN CN201180051334.6A patent/CN103179962B/zh active Active
- 2011-10-28 HU HUE11784418A patent/HUE034890T2/hu unknown
- 2011-10-28 EP EP11784418.3A patent/EP2632451B1/en active Active
- 2011-10-28 WO PCT/EP2011/005452 patent/WO2012055567A2/en active Application Filing
- 2011-10-28 CA CA2814371A patent/CA2814371C/en active Active
- 2011-10-28 LT LTEP11784418.3T patent/LT2632451T/lt unknown
- 2011-10-28 RS RS20171305A patent/RS56713B1/sr unknown
- 2011-10-28 US US13/880,139 patent/US20130217737A1/en not_active Abandoned
- 2011-10-28 JP JP2013535311A patent/JP6257326B2/ja active Active
- 2011-10-28 ES ES11784418.3T patent/ES2655084T3/es active Active
-
2014
- 2014-07-10 US US14/328,035 patent/US9468615B2/en active Active
-
2017
- 2017-11-28 HR HRP20171848TT patent/HRP20171848T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9468615B2 (en) | 2016-10-18 |
| LT2632451T (lt) | 2018-02-12 |
| DK2632451T3 (en) | 2017-12-18 |
| SI2632451T1 (en) | 2018-02-28 |
| US20130217737A1 (en) | 2013-08-22 |
| ES2655084T3 (es) | 2018-02-16 |
| NO2632451T3 (US20070167479A1-20070719-C00034.png) | 2018-03-17 |
| WO2012055567A2 (en) | 2012-05-03 |
| WO2012055567A3 (en) | 2012-07-05 |
| CN103179962A (zh) | 2013-06-26 |
| EP2632451B1 (en) | 2017-10-18 |
| US20140357722A1 (en) | 2014-12-04 |
| EP2632451A2 (en) | 2013-09-04 |
| CA2814371C (en) | 2019-03-19 |
| JP2013545730A (ja) | 2013-12-26 |
| HUE034890T2 (hu) | 2018-03-28 |
| CN103179962B (zh) | 2017-03-22 |
| PL2632451T3 (pl) | 2018-04-30 |
| RS56713B1 (sr) | 2018-03-30 |
| PT2632451T (pt) | 2017-12-14 |
| CA2814371A1 (en) | 2012-05-03 |
| JP6257326B2 (ja) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171848T1 (hr) | Upotreba malononitrilamida za neuropatsku bol | |
| JP2013545730A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2020037585A5 (US20070167479A1-20070719-C00034.png) | ||
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2015520151A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2014518266A5 (US20070167479A1-20070719-C00034.png) | ||
| IL273177B2 (en) | Fluorophenyl beta-hydroxyethylamines and their uses in the treatment of hyperglycemia | |
| JP2020505423A5 (US20070167479A1-20070719-C00034.png) | ||
| SI3004106T1 (en) | Dual selective PI3 delta and gamma inhibitors | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2018507886A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2020520957A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2019505529A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2021505575A5 (US20070167479A1-20070719-C00034.png) | ||
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| JP2012144537A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2019134416A (ru) | Фармацевтические композиции | |
| JP2015522037A5 (US20070167479A1-20070719-C00034.png) | ||
| CA3097053A1 (en) | Edaravone pharmaceutical composition | |
| EP2144887A1 (en) | Dosages and methods for the treatment of cancer | |
| PH12020551494A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2019531286A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2014513065A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2016105310A (ru) | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора |
